{"nctId":"NCT01523496","briefTitle":"Vitamin D Supplementation in HIV Youth","startDateStruct":{"date":"2011-12"},"conditions":["HIV Infections"],"count":190,"armGroups":[{"label":"HIV + Young Adults","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Vitamin D control dose","Drug: Vitamin D supplementation-"]},{"label":"HIV - Controls","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Vitamin D control dose","Drug: Vitamin D supplementation-"]}],"interventions":[{"name":"Vitamin D control dose","otherNames":["25(OH)D3 low dose"]},{"name":"Vitamin D supplementation-","otherNames":["25(OH)D3 medium dose or 25(OH)high dose"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ages 8-25\n* Documented HIV-1 infection\n* On stable antiretroviral therapy for \\> 3 months\n* Cumulative antiretroviral therapy of at least 6 months\n* 25(OH)D level \\< 30 ng/ml at screening\n\nExclusion Criteria:\n\n* \\> 400 IU daily regular vitamin D intake\n* Parathyroid/calcium disorders\n* Active malignancy\n* Pregnancy/intent to become pregnant/breastfeeding\n* Chronic infectious/inflammatory conditions\n* Creatinine clearance \\< 50 ml/min\n* Hemoglobin \\< 9.0 g/dL\n* Aspartate aminotransferase and alanine aminotransferase \\> 2.5 upper limit of normal\n* Diabetes requiring hypoglycemic agents\n* Known coronary artery disease\n* Inability to swallow pills","healthyVolunteers":true,"sex":"ALL","minimumAge":"8 Years","maximumAge":"25 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Changes in Serum 25(OH)D3 Levels","description":"Evaluate the dose-related efficacy of correction of Vitamin D deficiency for 25(OH)D3 levels in a group of HIV-infected children and young adults and a matched healthy control group in a randomized controlled study of different dosing regimens of oral Vitamin D supplementation: control dose (18,000 IU per month) or supplemented dose (medium 60,000IU per month or high dose 120,000IU/month )","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"7.5","spread":null},{"groupId":"OG003","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Vitamin D Binding Protein (VDBP)","description":"Evaluate the dose-related efficacy of vitamin D binding Protein in levels in the blood in a group of HIV-infected children and young adults and a matched healthy control group in a randomized controlled study of different dosing regimens of oral vitamin D supplementation.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"-8.9","spread":null},{"groupId":"OG002","value":"-11.3","spread":null},{"groupId":"OG003","value":"-11.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":36},"commonTop":[]}}}